In the news
31
Oct
2025
Rafiq Hasan discusses Complement Tx’s FDA IND clearance to advance CTx001 into Opti-GAIN Phase I/II Trial in GA secondary to AMD on BiotechTV
CEO Rafiq Hasan describes to BiotechTV's Amy Brown during an interview in London how this program works, and he compares and contrasts it to more traditional therapies that are on the market currently. Plus, and overview of Complement's other programs and operations.
Please click here to read more